Business
news
Economic vaccination: Do companies benefit from the race to find a solution for Corona?
When he embarked on the race to find a vaccine against Corona, it seemed that whoever reached the finish line first would win the spoils - buying massive shares of the public and raising the value of the company.
The difficulties, hopes and delays made the gamble complex and dangerous.
Is it worth it?
A short investment guide for leading companies
Tags
Vaccine
David Rosenthal
Sunday, 25 October 2020, 08:53
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments
The economic crisis following the corona: shops and businesses ...
Dimitri Tsignok, the suspect in the murder of his partner Anastasia Klein, ...
Beyoncé on Instagram
Finance Minister Katz meets with heads of disabled organizations: expresses appreciation ...
Director General of the Ministry of Health: Opening of studies in the ultra-Orthodox society ...
Steamery Fabric Razor
Right-wing MKs on anti-economic violence in the family law: ...
Cinema projector
Yoaz Handel enters his position as Minister of Communications: "Sees values ...
USA: Apple, Google, Amazon and Facebook were questioned in Congress about ...
The Prime Minister, at the police headquarters in Beit Dagan.
In the video: Obama at the Bayden rally in Pennsylvania (Photo: Reuters)
March, the month in which the corona plague broke out in full force, was also the opening shot for finding a vaccine.
More than 100 companies have started the process, and many are talking about the prestige of winning the race, in addition to the obvious medical contribution.
But above all, the financial aspect plays out.
These are companies whose market value usually reaches tens of billions of dollars.
Any steps in finding a cure / vaccine, or alternatively a failure in the process, can be fateful for shareholders.
We selected the five most talked about companies in this context - four companies developing vaccines and one that has developed a drug - for a brief review along with the analysts' recommendations as formulated on the economic website Marketwatch.
It is important to note, of course, that in this review there is no recommendation for the purchase of the shares, which is made in the opinion of the capitalist only.
Good to know (Promoted content)
Istanbul is open - an hour away from a natural and regular solution for female pattern baldness
Ayelet Geyer Company
To the full article
The unit whose product has already been approved by the FDA.
How does this help her financially?
Giliad (Photo: Reuters)
Astraznica
The relatively young British-Swedish society is the greatest hope of all for finding a vaccine for corona.
The hAdOx1 vaccine is considered to be the fastest and initial estimates were that it would be approved by the end of 2020, but at the moment it is highly doubtful whether this will happen.
The experiment has suffered from a number of glitches, including two in recent times.
It was first reported on September 8 that the condition of one of the experimenters had worsened, which led to a halt until it became clear that it was an inflammation of the spinal cord, a general side effect of viral diseases, and the experiment continued.
On October 15, an experimenter in Brazil died, the experiment was stopped and continued after it became clear that the vaccine injected into his body was a placebo at all.
On Friday, the FDA also approved the continuation of the experiment in the United States.
Stock Exchange:
London
Market value:
$ 135 billion.
Stock Review:
On March 16, the downturn in the markets, Astraznica fell to 6,221 points, but in early April announced that it would open a lab that could perform 30,000 corona tests a day and investors returned to it.
The breakthrough was recorded in July, when it joined the American IQVIA to increase the rate of the vaccine trial and the stock has already reached 9,200 points, but recently there have been mostly declines and today the stock stands at 7,943 points.
Marketwatch Recommendation: The
vast majority of analysts recommend buying.
Finding a vaccine could certainly have helped him before the election.
Trump (Photo: Tom Brenner, Reuters)
Johnson & Johnson
There is really no need to introduce this pharma giant, which has been active since 1886 and was forced to stop Phase 3 last week in an experiment similar to those of Astraznica, after one of the experimenters fell ill.
The experiment is expected to resume this week with the participation of 60,000 experimenters, most of them from Peru and South Africa.
Stock Exchange:
New York
Market value:
$ 360 billion
Stock Review:
Overall, Johnson & Johnson stuck to the general stock market narrative - a plunge in March, a rapid V recovery and a shuffle around the price levels it reached in late April.
The stock stands at 145 points, one more than it had on January 1st.
The possibility of a future vaccine does not seem to affect investors in her case.
Marketwatch Recommendation:
In general, there is encouragement to buy the stock, with 10 analysts recommending a purchase and six recommending a hold.
A long-standing success story.
Johnson & Johnson (Photo: Reuters)
Pfizer
Like its competitors, Pfizer is working on a vaccine that will be ready soon, and its advantage lies in the speed of production and distribution.
If the vaccine is ready in the coming months, the optimistic estimate is that by mid-2021 every American will be vaccinated against the corona.
Pfizer's initial market share will be huge with the introduction of the vaccine, about 50 percent of the population, but is expected to shrink to 25 percent when more vaccines emerge.
All this, of course, assuming you will be first or at least second in his approval.
Stock Exchange:
New York
Market value:
$ 210 billion
Stock Review:
Pfizer also had a difficult year with a drop in vigor and a rapid recovery.
The stock stands at 38 points and analysts have given it a target price of 42. Does that mean they think it is up?
Marketwatch Recommendation:
The answer to the previous question is "not really".
Unlike J&J, Pfizer's dominant recommendation is "hold".
There are those who recommend buying, but in general investors do not seem to believe in the company, whose last significant leap was recorded after the invention of Viagra in the late 90s and has been difficult ever since (hopefully you caught the punch).
The last time Pfizer made a real leap: with the invention of Viagra
Modern
Our great hope comes from the youngest company (founded in 2010) with the lowest market value.
Israel acquired in June the possibility of being among the first to purchase vaccines from modernity, so if the vaccine is approved, it will make its way to us soon.
The company is currently testing the vaccine on 30,000 testers and we will have to wait and see if Phase 3 is crowned a success.
Stock Exchange:
Nasdaq
Market value:
$ 28 billion
Stock Review:
Since she is small and relatively anonymous, certainly less well known than the big sisters in the field, and also one of the first to come out with the vaccine news on the way, Modern broke out nicely this year and even managed the March crisis that caused competitors to plummet.
She started the year with 18 points, reached 95 points and currently stands at 70 points.
Those who were educated to invest in it in January have already purchased one or two islands.
Marketwatch Recommendation:
Apparently the modern and future company's vaccine is particularly promising, as the consensus regarding the stock is high.
12 analysts recommend buying, 2 strong and one, who does not really believe in the vaccine, recommends selling.
Our hope.
Modern experiment (Photo: Reuters)
Giliad
Unlike the four companies mentioned above, Giliad was not working on a vaccine but on a drug - Remediesbir, which became the first FDA-approved anti-corona.
Shortly after President Donald Trump was treated with the drug, researchers issued an opinion stating that Remedial Siberia does not have too much of an impact on critically ill patients.
It mainly shortens the duration of recovery and if given on time, may even prevent its development and the hospitalization involved.
2 million doses will be distributed in the near future in the US, and if the drug does show results - the sky may be the limit.
Stock Exchange:
Nasdaq
Market value:
$ 75 billion
Stock Review
: This has been a year of ups and downs for Gilead, and surprisingly the pendulum has tilted to the side of the downs.
The company suffered from volatility throughout the period, and after exceeding 80 points several times, fell back and now stands at 60.8 points, about 8 percent lower than a campaign earlier this year, even before the Corona story began.
Marketwatch recommendation: A
low price per share can be an opportunity in many cases, but Gilead also suffers from a marked lack of trust among experts - 15 analysts recommend "hold" and 11 on buy.
Currently, the stock continues to shuffle in forecasts as well.
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments
